BIOMAT Database Logo BIOMAT Database Logo

Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles. 2016

Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
From the Centro de Investigación Lilly, Eli Lilly and Co., Alcobendas 28108, Spain and.

Therapeutic intervention to activate the glucagon-like peptide-1 receptor (GLP-1R) enhances glucose-dependent insulin secretion and improves energy balance in patients with type 2 diabetes mellitus. Studies investigating mechanisms whereby peptide ligands activate GLP-1R have utilized mutagenesis, receptor chimeras, photo-affinity labeling, hydrogen-deuterium exchange, and crystallography of the ligand-binding ectodomain to establish receptor homology models. However, this has not enabled the design or discovery of drug-like non-peptide GLP-1R activators. Recently, studies investigating 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP), a GLP-1R-positive allosteric modulator, determined that Cys-347 in the GLP-1R is required for positive allosteric modulator activity via covalent modification. To advance small molecule activation of the GLP-1R, we characterized the insulinotropic mechanism of BETP. In guanosine 5'-3-O-(thio)triphosphate binding and INS1 832-3 insulinoma cell cAMP assays, BETP enhanced GLP-1(9-36)-NH2-stimulated cAMP signaling. Using isolated pancreatic islets, BETP potentiated insulin secretion in a glucose-dependent manner that requires both the peptide ligand and GLP-1R. In studies of the covalent mechanism, PAGE fluorography showed labeling of GLP-1R in immunoprecipitation experiments from GLP-1R-expressing cells incubated with [(3)H]BETP. Furthermore, we investigated whether other reported GLP-1R activators and compounds identified from screening campaigns modulate GLP-1R by covalent modification. Similar to BETP, several molecules were found to enhance GLP-1R signaling in a Cys-347-dependent manner. These chemotypes are electrophiles that react with GSH, and LC/MS determined the cysteine adducts formed upon conjugation. Together, our results suggest covalent modification may be used to stabilize the GLP-1R in an active conformation. Moreover, the findings provide pharmacological guidance for the discovery and characterization of small molecule GLP-1R ligands as possible therapeutics.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067757 Glucagon-Like Peptide-1 Receptor A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS). GLP-1 Receptor,GLP-1R Receptor,GLP1R Protein,GLP1R Receptor,GLP 1 Receptor,GLP 1R Receptor,Glucagon Like Peptide 1 Receptor,Peptide-1 Receptor, Glucagon-Like,Protein, GLP1R,Receptor, GLP-1,Receptor, GLP-1R,Receptor, GLP1R,Receptor, Glucagon-Like Peptide-1
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin

Related Publications

Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
Potent Prearranged Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor.
August 2017, ChemistryOpen,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.
June 2021, Nature communications,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
December 2012, Molecular pharmacology,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
2-Aminothiophene derivatives as a new class of positive allosteric modulators of glucagon-like peptide 1 receptor.
June 2022, Chemical biology & drug design,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
An Overview, Advantages and Therapeutic Potential of Nonpeptide Positive Allosteric Modulators of Glucagon-Like Peptide-1 Receptor.
March 2019, ChemMedChem,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor.
October 2007, Bioorganic & medicinal chemistry letters,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor-Positive Lesions.
November 2020, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
March 2020, Journal of medicinal chemistry,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
January 2012, PloS one,
Ana B Bueno, and Aaron D Showalter, and David B Wainscott, and Cynthia Stutsman, and Aranzazu Marín, and James Ficorilli, and Over Cabrera, and Francis S Willard, and Kyle W Sloop
Ago-allosteric modulators of human glucagon-like peptide 2 receptor.
October 2012, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!